Previous Close | 7.75 |
Open | 7.75 |
Bid | 9.70 |
Ask | 11.35 |
Strike | 4.50 |
Expire Date | 2024-06-07 |
Day's Range | 7.75 - 7.75 |
Contract Range | N/A |
Volume | |
Open Interest | 2 |
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in the 2024 Jefferies Global Healthcare Conference.
Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Whitefort Capital wants biopharmaceutical firm Arbutus to stop issuing stock. Shah Capital ended a proxy campaign against biotech Novavax.